These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23615868)

  • 1. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
    Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
    Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.
    Roesch B; Corcoran M; Haffey M; Stevenson A; Wang P; Purkayastha J; Martin P; Ermer J
    Drugs R D; 2013 Mar; 13(1):53-61. PubMed ID: 23519656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.
    Ermer J; Haffey MB; Richards C; Lasseter K; Roesch B; Purkayastha J; Corcoran M; Harlin B; Martin P
    Clin Drug Investig; 2013 Apr; 33(4):243-54. PubMed ID: 23512639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
    Ermer J; Corcoran M; Lasseter K; Martin PT
    Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
    Boellner SW; Stark JG; Krishnan S; Zhang Y
    Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
    Wilens TE; McBurnett K; Turnbow J; Rugino T; White C; Youcha S
    J Atten Disord; 2017 Jan; 21(2):110-119. PubMed ID: 24071772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T; Dirks B; Adeyi B; Scheckner B
    BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; McBurnett K; White C; Youcha S
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults.
    Faison SL; Fry N; Adewole T; Odebo O; Wang Z; Maletic V; Nasser A
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):155-162. PubMed ID: 33587403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
    Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
    Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.